Streamlining Cell Manufacturing: The Impact of Pala

BioCell Innovations Pte Ltd, a Singapore-based biotechnology company, is dedicated to advancing cell and gene therapy technologies. With a commitment to developing safer and more effective personalized treatments, the company focuses on minimizing risks such as cytokine release syndrome (CRS) in CAR-T therapies. By leveraging proprietary technology and strategic collaborations, BioCell Innovations continues to drive progress in patient care and therapeutic safety.

Dr. Paula Lam, Chief Scientific Officer at BioCell Innovations, leads research efforts focused on engineering novel cell- and viral-based gene delivery tools, optimizing viral vector packaging, and unraveling the mechanisms of tumor initiation and progression. Her team has developed a proprietary CAR construct development and cell manufacturing process aimed at reducing potential adverse events while maintaining robust anti-tumor efficacy.

Ensuring Efficiency and Reproducibility in Cell Manufacturing

A critical component of BioCell Innovations' success lies in its novel cell manufacturing process, which integrates advanced engineering techniques with cutting-edge CAR lentiviral vectors. These include humanized CD19 CAR lentiviral vectors designed to enhance therapeutic outcomes while mitigating severe immune responses.

Dr. Lam and her team work with a variety of cell types, including 293T and T cells, depending on the experiment. One of their key goals is to streamline single cell sorting and clone identification to improve the efficiency and reproducibility of cell manufacturing.

A Reliable and Effective Cell Sorting Solution

During their workflow optimization, BioCell Innovations initially encountered challenges with another sorting system. However, after implementing the Pala Single Cell Dispenser, the team saw immediate improvements.

"We had earlier faced some issues with the demo unit of a different platform. However, Pala runs
smoothly for us. We’ve had no issues with Pala," Dr. Lam noted.

Using Pala, the team successfully sorted and identified single 293T suspension clones, leading to the production of high lentiviral titers. The sorted cells expanded well and were successfully cryopreserved for further research and development.

A Trusted Tool for Cell Line Engineering

The introduction of Pala into BioCell Innovations' workflow has significantly improved sorting efficiency, increased success rates, and facilitated additional cell line engineering efforts. The simple operation and reliability of Pala make it an ideal tool for scientists aiming to optimize single cell sorting and clone selection.

Dr. Lam and her team are highly satisfied with Pala’s performance and its role in enhancing their research capabilities. "Very happy with Pala—I will recommend it should opportunities arise to do so," she affirmed.

With the integration of cutting-edge tools like Pala, BioCell Innovations continues to advance the field of cell and gene therapy, bringing safer and more effective treatments to patients in need.